Precision Medicine Approach to Unravel the Risk Factors for Renal, Cardiovascular, Ophthalmologic, Neurologic and Hepatic Complications of Metabolic Disorders
Key facts
- Who runs it
- Institut National de la Santé Et de la Recherche Médicale, France
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 3 May 2022
- Expected to end
- 3 May 2032
- Type of study
- Observational
- Record updated
- 16 May 2025
- Why it stopped
- No inclusion within 2 years of approval by CPP
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Adult persons, male or female, age ≥ 18 and ≤ 65 years
- Persons able to understand the information provided and to object to it (at the discretion of the investigator)
- Patient affiliated to a social security system
- Patient willing to sign an informed consent form
- Patient with the following metabolic profile Diabetic (of any type) treated or not (diabetes will be defined by a fasting blood glucose > 7mM or a HbA1c > 6.5% or by the use of an antidiabetic treatment) AND/OR Obese patient (BMI > 30 kg/m2) treated or not
- Patient with evidence of renal parenchymal damage defined by an albuminuria/creatinuria ratio ≥ 3 mg/mmol (30mg/g), AND/OR a glomerular filtration rate estimated by the CKD-EPI (eDFG) formula classifying the patient as stage 2 to 3a of the KDIGO classification (i.e., 90ml/min/1.73 m2 > GFR > 45ml/min), AND/OR a renal lithiasis
Who cannot take part
- Patient with or who has had any of the following complications: symptomatic coronary artery disease, symptomatic peripheral arterial disease, previous stroke, previous myocardial infarction, heart failure ≥ stage B, dementia, liver fibrosis, hepatocarcinoma
- Patient with advanced chronic kidney disease defined as GFR < 45ml/min/1.73 m²
- Patient deprived of liberty
- Person subject to a legal protection measure (guardianship, curatorship or safeguard of justice)
- Patient refusing to participate in the study
- Pregnant, parturient or nursing woman
- Patient in emergency situation
- Contraindication to Iohexol injection
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
There is currently no way to predict the progression of chronic kidney disease in patients with metabolic disease(s). Furthermore, the mechanisms responsible for the development and/or progression of complications remain largely unknown.
Read full original descriptionShow less
In order to identify the predictive factors and/or mechanisms involved in the different complications of these diseases, we propose an approach coupling :
* a classical phenotypic characterization (clinical, biological, imaging) of the patients * high-throughput screening of the genome, transcriptome, metabolome, proteome, and immunophenotyping.
According to our hypothesis, this approach should allow :
* Early detection of complications * Classification of patients in homogeneous groups of patients with identical evolution * Identification of the molecular mechanisms involved.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 16 May 2025